Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jasper Therapeutics (JSPR) shares plummeted nearly 55% on Monday, driven by an update on its briquilimab BEACON study for chronic spontaneous urticaria (CSU) that revealed mixed results. While early single-dose cohorts demonstrated strong efficacy with 89% complete response, a confounding issue with a drug product lot in other cohorts necessitates further patient enrollment and delays the Phase 2b CSU study commencement to mid-2026. This setback has prompted Jasper to halt briquilimab development in asthma and SCID, and implement cost-cutting measures, signaling a significant narrowing of its pipeline focus and prompting sharp investor reaction despite promising initial clinical data.

Analysis

Jasper Therapeutics (JSPR) experienced a severe market repricing, with its stock falling approximately 55% on trading volume nearly 40 times its daily average. The catalyst was a clinical program update that presented a deeply conflicting picture. While the BEACON study of briquilimab for chronic spontaneous urticaria (CSU) demonstrated high efficacy in initial single-dose cohorts, with 89% of participants achieving a complete response, this positive signal was overshadowed by a critical operational failure. A compromised drug product lot invalidated the results from two other key cohorts, forcing the company to enroll additional patients. This directly pushes the commencement of the pivotal Phase 2b study to mid-2026, a significant delay that materially extends the timeline to potential commercialization. In response to this setback and to conserve capital, management is halting development of briquilimab in asthma and SCID and is implementing cost-cutting measures, including a potential restructuring. This strategic pivot narrows Jasper to a single-asset story focused on CSU, concentrating risk and signaling concerns over its financial runway.

Key Decisions for Investors

• Investors should reassess their thesis based on the significantly extended development timeline to mid-2026 and the heightened single-asset risk following the termination of the asthma and SCID programs.
• The drug product lot failure introduces a critical manufacturing and operational risk; closely monitor the results of the company's investigation, as any systemic issue could jeopardize the entire briquilimab platform.
• Given the planned restructuring and need to extend the cash runway, scrutinize the company's cash burn rate and anticipate the high probability of future dilutive financing before the next major clinical milestone.
• While the underlying efficacy data in clean cohorts is promising, any new or existing positions should be considered high-risk until there is full clarity on the manufacturing issue and successful data replication from the newly enrolled cohorts in Q4 2025.